High‐throughput sequencing detection and ensartinib treatment of lung cancer harboring NTRK1 fusion
Main Authors: | Zhengbo Song, Chunwei Xu, Xingxiang Pu, Youcai Zhu, Wenxian Wang, Xingliang Li, Yanqiu Gao, Wenliang Zhu, Yunwei He, Lin Wu, Li Mao, Li Chen, Ming Chen |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2021-02-01
|
Series: | Cancer Communications |
Online Access: | https://doi.org/10.1002/cac2.12133 |
Similar Items
-
Molecular and clinicopathologic features of gliomas harboring NTRK fusions
by: Matthew Torre, et al.
Published: (2020-07-01) -
Pharmacology and Clinical Evaluation of Ensartinib Hydrochloride Capsule
by: Yang WANG, et al.
Published: (2020-08-01) -
ROS1-ADGRG6: a case report of a novel ROS1 oncogenic fusion variant in lung adenocarcinoma and the response to crizotinib
by: Shuguang Xu, et al.
Published: (2019-08-01) -
Antitumor Activity of Larotrectinib in Tumors Harboring NTRK Gene Fusions: A Short Review on the Current Evidence [Corrigendum]
by: Ricciuti B, et al.
Published: (2020-05-01) -
Antitumor activity of larotrectinib in tumors harboring NTRK gene fusions: a short review on the current evidence
by: Ricciuti B, et al.
Published: (2019-04-01)